Share this video  

ASCO GI 2023 | Identifying patients with solid tumors for HLA loss of heterozygosity

J. Randolph Hecht, MD, University of California, Los Angeles, CA, provides an overview of BASECAMP-1 (NCT04981119), an observational study analyzing how solid tumors undergo human leukocyte antigen (HLA) loss of heterozygosity and subsequent leukapheresis for potential logic-gated CAR-T cell therapies. Patients with HLA-A*02 positive tumors were successfully identified, and is a feasible method for patient selection in future CAR-T cell trials. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.